Late anthracycline cardiotoxicity protection by dextrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up

ELBL, Lubomír, Hana HRSTKOVÁ, Iva TOMÁŠKOVÁ and Jaroslav MICHÁLEK. Late anthracycline cardiotoxicity protection by dextrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up (Late anthracyclone cardiotoxicity protection by dextrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up). Support Care Cancer. Heidelberg, Germany: Springer-Verlag, 2006, vol. 14, No 2, p. 128-136. ISSN 0941-4355.

Basic information

Original name

Late anthracycline cardiotoxicity protection by dextrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up

Name in Czech

Prevence pozdní kardiotoxicity daxtrazoxanem (ICRF-187) u dětských pacientů

Authors

ELBL, Lubomír, Hana HRSTKOVÁ, Iva TOMÁŠKOVÁ and Jaroslav MICHÁLEK

Edition

Support Care Cancer, Heidelberg, Germany, Springer-Verlag, 2006, 0941-4355

---

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30209 Paediatrics

Country of publisher

Germany

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.905

Organization unit

Faculty of Medicine

UT WoS

000234732800004

Keywords (in Czech)

Dextrazoxan, kardiotoxicita, děti

Keywords in English

Dextrazoxane; anthracycline; cardiotoxicity;

Tags

anthracycline, cardiotoxicity, Dextrazoxane

Tags

Reviewed

---

Abstract

V originále

The authors conducted a retrospective study to determine whwther dexthrazoxane (ICRF-187) would reduce late anthracycline -inducted cardiotexicity in patients treated in childhood for hematology malignance.

In Czech

Dextrazoxan rtedukuje riziko pozdní koinické a subklinické kardiotoxicity a nesnižuj eúčinek chemoterqpie a celkové přežití během mediánu sledování 7 let